Number of items: 9.
2024
McGuigan, M.-C., Hadjicosti, R., Cameron, A. J. , Coats, M., Chang, D. , Dickson, E. J., Holroyd, D., McKay, C. J. and Jamieson, N. B.
(2024)
The surveillance strategy for Intraductal Pancreatic Mucinous Neoplasms: Criteria for discontinuation.
Annals of Surgery,
(Accepted for Publication)
Lucocq, J. et al.
(2024)
Precursor epithelial subtypes of adenocarcinoma arising from intraductal papillary mucinous neoplasms (A-IPMN): clinicopathological features, recurrence and response to adjuvant chemotherapy.
Annals of Surgical Oncology, 31(10),
pp. 7023-7032.
(doi: 10.1245/s10434-024-15677-z)
(PMID:38961040)
Stankey, C.T. et al.
(2024)
A disease-associated gene desert directs macrophage inflammation through ETS2.
Nature, 630(8016),
pp. 447-456.
(doi: 10.1038/s41586-024-07501-1)
(PMID:38839969)
Robertson, F. P., Cameron, A. , Spiers, H. V.M., Joseph, N., Taylor, E., Ratnayake, B., Jamieson, N. B. and Pandanaboyana, S.
(2024)
Evidence for molecular subtyping in pancreatic ductal adenocarcinoma: A systematic review.
HPB, 26(5),
pp. 609-617.
(doi: 10.1016/j.hpb.2024.02.001)
(PMID:38401998)
Lucocq, J. et al.
(2024)
Adjuvant chemotherapy for adenocarcinoma arising from intraductal papillary mucinous neoplasia: multicentre ADENO-IPMN study.
British Journal of Surgery, 111(4),
znae100.
(doi: 10.1093/bjs/znae100)
(PMID:38659247)
Lucocq, J. et al.
(2024)
Long-term outcomes following resection of Adenocarcinoma arising from Intraductal Papillary Mucinous Neoplasm (A-IPMN) versus Pancreatic Ductal Adenocarcinoma (PDAC): a propensity-score matched analysis.
Annals of Surgery,
(doi: 10.1097/SLA.0000000000006272)
(PMID:38516777)
(Early Online Publication)
2023
Lucocq, J. et al.
(2023)
Risk of recurrence after surgical resection for adenocarcinoma arising from intraductal papillary mucinous neoplasia (IPMN) with patterns of distribution and treatment.
Annals of Surgery, 280(1),
pp. 126-135.
(doi: 10.1097/sla.0000000000006144)
(PMID:37873663)
Wood, C. S. et al.
(2023)
Spatially resolved transcriptomics deconvolutes prognostic histological subgroups in patients with colorectal cancer and synchronous liver metastases.
Cancer Research, 83(8),
pp. 1329-1344.
(doi: 10.1158/0008-5472.CAN-22-2794)
(PMID:37057593)
(PMCID:PMC10102851)
2022
Fisher, N. C. et al.
(2022)
Biological misinterpretation of transcriptional signatures in tumour samples can unknowingly undermine mechanistic understanding and faithful alignment with preclinical data.
Clinical Cancer Research, 28(18),
pp. 4056-4069.
(doi: 10.1158/1078-0432.CCR-22-1102)
(PMID:35792866)
(PMCID:PMC9475248)
This list was generated on Thu Nov 21 02:04:54 2024 GMT.